Stem definition | Drug id | CAS RN |
---|---|---|
2274 | 58-38-8 |
Dose | Unit | Route |
---|---|---|
0.10 | g | O |
50 | mg | P |
0.10 | g | R |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.10 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 3.83 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 15 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 22 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 16 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 9 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 23, 1956 | FDA | GLAXOSMITHKLINE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 346.01 | 11.57 | 467 | 52489 | 97200 | 50454968 |
Drug ineffective | 301.57 | 11.57 | 251 | 52705 | 819082 | 49733086 |
Disease progression | 257.20 | 11.57 | 402 | 52554 | 95464 | 50456704 |
Dehydration | 236.43 | 11.57 | 504 | 52452 | 151945 | 50400223 |
Diarrhoea | 216.94 | 11.57 | 1196 | 51760 | 587280 | 49964888 |
Plasma cell myeloma | 216.86 | 11.57 | 212 | 52744 | 31110 | 50521058 |
Nausea | 213.56 | 11.57 | 1361 | 51595 | 704037 | 49848131 |
White blood cell count decreased | 206.99 | 11.57 | 408 | 52548 | 116314 | 50435854 |
Vomiting | 197.47 | 11.57 | 977 | 51979 | 459781 | 50092387 |
Platelet count decreased | 147.95 | 11.57 | 326 | 52630 | 100400 | 50451768 |
Contraindicated product administered | 141.25 | 11.57 | 3 | 52953 | 148955 | 50403213 |
Fatigue | 140.09 | 11.57 | 1236 | 51720 | 706365 | 49845803 |
Death | 125.72 | 11.57 | 671 | 52285 | 324708 | 50227460 |
Neutropenia | 122.86 | 11.57 | 387 | 52569 | 147578 | 50404590 |
Synovitis | 115.47 | 11.57 | 3 | 52953 | 123862 | 50428306 |
Systemic lupus erythematosus | 113.19 | 11.57 | 9 | 52947 | 140613 | 50411555 |
Arthropathy | 109.79 | 11.57 | 17 | 52939 | 157889 | 50394279 |
Constipation | 108.78 | 11.57 | 433 | 52523 | 185275 | 50366893 |
Malignant neoplasm progression | 99.41 | 11.57 | 220 | 52736 | 67904 | 50484264 |
Asthenia | 95.93 | 11.57 | 616 | 52340 | 318426 | 50233742 |
Toxicity to various agents | 95.08 | 11.57 | 52 | 52904 | 212447 | 50339721 |
Therapeutic product effect decreased | 93.77 | 11.57 | 15 | 52941 | 136035 | 50416133 |
Joint swelling | 90.96 | 11.57 | 74 | 52882 | 245212 | 50306956 |
Decreased appetite | 81.98 | 11.57 | 421 | 52535 | 200502 | 50351666 |
Glossodynia | 79.05 | 11.57 | 13 | 52943 | 115556 | 50436612 |
Blood magnesium decreased | 76.20 | 11.57 | 75 | 52881 | 11085 | 50541083 |
Neutrophil count decreased | 75.61 | 11.57 | 156 | 52800 | 45870 | 50506298 |
Abdominal pain | 72.06 | 11.57 | 458 | 52498 | 235770 | 50316398 |
Full blood count decreased | 71.68 | 11.57 | 102 | 52854 | 22244 | 50529924 |
Neovascularisation | 71.35 | 11.57 | 30 | 52926 | 983 | 50551185 |
Neoplasm progression | 69.50 | 11.57 | 116 | 52840 | 29041 | 50523127 |
Neuropathy peripheral | 69.43 | 11.57 | 241 | 52715 | 96516 | 50455652 |
Hospice care | 66.01 | 11.57 | 52 | 52904 | 5720 | 50546448 |
Thrombosis | 65.88 | 11.57 | 166 | 52790 | 55667 | 50496501 |
Pericarditis | 63.39 | 11.57 | 5 | 52951 | 78684 | 50473484 |
Pleural effusion | 62.94 | 11.57 | 208 | 52748 | 81246 | 50470922 |
Heart rate abnormal | 61.45 | 11.57 | 43 | 52913 | 3949 | 50548219 |
Therapeutic product effect incomplete | 61.03 | 11.57 | 11 | 52945 | 91504 | 50460664 |
Condition aggravated | 60.26 | 11.57 | 139 | 52817 | 296919 | 50255249 |
Akathisia | 59.36 | 11.57 | 57 | 52899 | 8172 | 50543996 |
Carbohydrate antigen 125 increased | 58.83 | 11.57 | 35 | 52921 | 2432 | 50549736 |
Rheumatoid arthritis | 56.15 | 11.57 | 78 | 52878 | 202472 | 50349696 |
Lymphadenitis | 53.88 | 11.57 | 34 | 52922 | 2626 | 50549542 |
Clostridium difficile infection | 53.80 | 11.57 | 96 | 52860 | 25343 | 50526825 |
Gangrene | 53.07 | 11.57 | 42 | 52914 | 4650 | 50547518 |
Completed suicide | 51.10 | 11.57 | 38 | 52918 | 131851 | 50420317 |
Small intestinal obstruction | 51.02 | 11.57 | 73 | 52883 | 15995 | 50536173 |
Arterial occlusive disease | 50.06 | 11.57 | 41 | 52915 | 4767 | 50547401 |
Infusion related reaction | 49.32 | 11.57 | 63 | 52893 | 169494 | 50382674 |
Thrombocytopenia | 48.21 | 11.57 | 262 | 52694 | 127411 | 50424757 |
Red blood cell count decreased | 47.90 | 11.57 | 108 | 52848 | 33727 | 50518441 |
Drug abuse | 47.66 | 11.57 | 4 | 52952 | 59842 | 50492326 |
Drug intolerance | 47.30 | 11.57 | 99 | 52857 | 219005 | 50333163 |
Swelling | 46.60 | 11.57 | 87 | 52869 | 200785 | 50351383 |
Cytokine release syndrome | 46.32 | 11.57 | 51 | 52905 | 8583 | 50543585 |
Maternal exposure during pregnancy | 45.82 | 11.57 | 60 | 52896 | 159718 | 50392450 |
Injection site pain | 45.63 | 11.57 | 30 | 52926 | 110994 | 50441174 |
Colitis | 44.86 | 11.57 | 114 | 52842 | 38415 | 50513753 |
Pancytopenia | 44.42 | 11.57 | 190 | 52766 | 83840 | 50468328 |
Lower respiratory tract infection | 42.96 | 11.57 | 23 | 52933 | 95178 | 50456990 |
Wound | 42.92 | 11.57 | 29 | 52927 | 105765 | 50446403 |
Coma | 42.17 | 11.57 | 5 | 52951 | 56874 | 50495294 |
Hepatic enzyme increased | 42.11 | 11.57 | 49 | 52907 | 137331 | 50414837 |
Injection site erythema | 42.10 | 11.57 | 13 | 52943 | 74923 | 50477245 |
Pain | 41.44 | 11.57 | 397 | 52559 | 578506 | 49973662 |
Pneumonitis | 39.35 | 11.57 | 92 | 52864 | 29418 | 50522750 |
Palmar-plantar erythrodysaesthesia syndrome | 38.90 | 11.57 | 73 | 52883 | 20025 | 50532143 |
Weight decreased | 38.54 | 11.57 | 377 | 52579 | 220868 | 50331300 |
Failure to thrive | 38.41 | 11.57 | 40 | 52916 | 6318 | 50545850 |
General physical health deterioration | 38.31 | 11.57 | 56 | 52900 | 142378 | 50409790 |
Pneumonia | 37.28 | 11.57 | 579 | 52377 | 377822 | 50174346 |
Treatment failure | 36.16 | 11.57 | 55 | 52901 | 137582 | 50414586 |
Paradoxical drug reaction | 35.68 | 11.57 | 30 | 52926 | 3617 | 50548551 |
Intentional overdose | 34.83 | 11.57 | 11 | 52945 | 62493 | 50489675 |
Hair colour changes | 34.33 | 11.57 | 26 | 52930 | 2698 | 50549470 |
Alopecia areata | 34.17 | 11.57 | 20 | 52936 | 1348 | 50550820 |
Blood creatine increased | 33.65 | 11.57 | 33 | 52923 | 4854 | 50547314 |
Hair texture abnormal | 33.57 | 11.57 | 29 | 52927 | 3627 | 50548541 |
Injection site reaction | 33.38 | 11.57 | 6 | 52950 | 50026 | 50502142 |
Haemoglobin decreased | 32.35 | 11.57 | 236 | 52720 | 126980 | 50425188 |
Mobility decreased | 32.31 | 11.57 | 22 | 52934 | 79926 | 50472242 |
Anaemia | 31.98 | 11.57 | 404 | 52552 | 252052 | 50300116 |
Discomfort | 31.78 | 11.57 | 40 | 52916 | 108340 | 50443828 |
Hypokalaemia | 31.48 | 11.57 | 178 | 52778 | 87814 | 50464354 |
Blood potassium decreased | 30.92 | 11.57 | 97 | 52859 | 36848 | 50515320 |
Rectal cancer metastatic | 30.39 | 11.57 | 11 | 52945 | 239 | 50551929 |
Off label use | 30.33 | 11.57 | 334 | 52622 | 474092 | 50078076 |
Hyponatraemia | 30.22 | 11.57 | 188 | 52768 | 95951 | 50456217 |
Folliculitis | 30.21 | 11.57 | 3 | 52953 | 39222 | 50512946 |
Back pain | 29.97 | 11.57 | 357 | 52599 | 219673 | 50332495 |
Mucosal inflammation | 29.65 | 11.57 | 101 | 52855 | 40041 | 50512127 |
Suicide attempt | 29.01 | 11.57 | 9 | 52947 | 51723 | 50500445 |
Irritable bowel syndrome | 28.75 | 11.57 | 9 | 52947 | 51432 | 50500736 |
Taste disorder | 28.18 | 11.57 | 39 | 52917 | 8285 | 50543883 |
Hypophagia | 28.17 | 11.57 | 78 | 52878 | 27650 | 50524518 |
Sepsis | 27.95 | 11.57 | 236 | 52720 | 132689 | 50419479 |
Musculoskeletal stiffness | 27.74 | 11.57 | 58 | 52898 | 128423 | 50423745 |
Drug hypersensitivity | 26.97 | 11.57 | 390 | 52566 | 250620 | 50301548 |
Knee arthroplasty | 26.94 | 11.57 | 3 | 52953 | 35843 | 50516325 |
Psoriatic arthropathy | 26.70 | 11.57 | 8 | 52948 | 47024 | 50505144 |
Muscle twitching | 26.15 | 11.57 | 53 | 52903 | 15378 | 50536790 |
Oral pain | 26.01 | 11.57 | 71 | 52885 | 24962 | 50527206 |
Injection site swelling | 25.81 | 11.57 | 6 | 52950 | 41767 | 50510401 |
Dysgeusia | 25.38 | 11.57 | 94 | 52862 | 38822 | 50513346 |
Exposure during pregnancy | 24.99 | 11.57 | 56 | 52900 | 120959 | 50431209 |
Weight increased | 24.62 | 11.57 | 118 | 52838 | 201773 | 50350395 |
Red cell distribution width increased | 24.45 | 11.57 | 37 | 52919 | 8522 | 50543646 |
Overdose | 24.17 | 11.57 | 42 | 52914 | 99685 | 50452483 |
Pyrexia | 23.31 | 11.57 | 541 | 52415 | 379662 | 50172506 |
Drug interaction | 23.01 | 11.57 | 119 | 52837 | 199502 | 50352666 |
Deep vein thrombosis | 22.81 | 11.57 | 143 | 52813 | 73161 | 50479007 |
Skin exfoliation | 22.60 | 11.57 | 82 | 52874 | 33530 | 50518638 |
Gastric disorder | 22.39 | 11.57 | 75 | 52881 | 29473 | 50522695 |
Arthralgia | 22.35 | 11.57 | 324 | 52632 | 438378 | 50113790 |
Laboratory test abnormal | 22.32 | 11.57 | 64 | 52892 | 23144 | 50529024 |
Hypersensitivity | 22.22 | 11.57 | 133 | 52823 | 215028 | 50337140 |
Ill-defined disorder | 22.13 | 11.57 | 15 | 52941 | 54639 | 50497529 |
Lymphadenopathy | 21.92 | 11.57 | 81 | 52875 | 33418 | 50518750 |
Cholestasis of pregnancy | 21.77 | 11.57 | 14 | 52942 | 1117 | 50551051 |
Hip arthroplasty | 21.76 | 11.57 | 3 | 52953 | 30426 | 50521742 |
C-reactive protein increased | 21.13 | 11.57 | 23 | 52933 | 66451 | 50485717 |
Red blood cell sedimentation rate increased | 20.81 | 11.57 | 3 | 52953 | 29413 | 50522755 |
Autoimmune nephritis | 20.74 | 11.57 | 9 | 52947 | 319 | 50551849 |
Hypoxia | 20.70 | 11.57 | 107 | 52849 | 51016 | 50501152 |
Extrapyramidal disorder | 20.63 | 11.57 | 41 | 52915 | 11729 | 50540439 |
Abdominal discomfort | 20.49 | 11.57 | 150 | 52806 | 231491 | 50320677 |
Fibromyalgia | 20.09 | 11.57 | 11 | 52945 | 44967 | 50507201 |
Dry skin | 20.05 | 11.57 | 94 | 52862 | 43097 | 50509071 |
Pulmonary embolism | 19.51 | 11.57 | 177 | 52779 | 101527 | 50450641 |
Tumour marker increased | 19.43 | 11.57 | 22 | 52934 | 3818 | 50548350 |
Loss of personal independence in daily activities | 19.36 | 11.57 | 27 | 52929 | 70023 | 50482145 |
Skull fracture | 19.17 | 11.57 | 12 | 52944 | 914 | 50551254 |
Nasopharyngitis | 19.01 | 11.57 | 121 | 52835 | 192806 | 50359362 |
Madarosis | 18.97 | 11.57 | 18 | 52938 | 2542 | 50549626 |
Plasma cell myeloma recurrent | 18.40 | 11.57 | 18 | 52938 | 2640 | 50549528 |
Breast cancer metastatic | 18.04 | 11.57 | 36 | 52920 | 10328 | 50541840 |
Injection site bruising | 17.92 | 11.57 | 8 | 52948 | 36760 | 50515408 |
Injection site pruritus | 17.88 | 11.57 | 10 | 52946 | 40401 | 50511767 |
Product use issue | 17.85 | 11.57 | 88 | 52868 | 149387 | 50402781 |
Mental status changes | 17.62 | 11.57 | 80 | 52876 | 36192 | 50515976 |
Abortion spontaneous | 17.55 | 11.57 | 11 | 52945 | 41761 | 50510407 |
Acquired cystic kidney disease | 17.47 | 11.57 | 5 | 52951 | 49 | 50552119 |
Intentional product misuse | 17.41 | 11.57 | 14 | 52942 | 46720 | 50505448 |
Anuria | 17.16 | 11.57 | 37 | 52919 | 11207 | 50540961 |
Coronary artery disease | 16.97 | 11.57 | 5 | 52951 | 29721 | 50522447 |
Lymphocyte count decreased | 16.70 | 11.57 | 63 | 52893 | 26244 | 50525924 |
Morbid thoughts | 16.45 | 11.57 | 9 | 52947 | 533 | 50551635 |
Streptococcal bacteraemia | 16.38 | 11.57 | 13 | 52943 | 1445 | 50550723 |
Impaired healing | 16.36 | 11.57 | 30 | 52926 | 69756 | 50482412 |
Clostridium difficile colitis | 16.17 | 11.57 | 48 | 52908 | 17694 | 50534474 |
Psoriasis | 15.87 | 11.57 | 30 | 52926 | 68970 | 50483198 |
Multiple sclerosis relapse | 15.84 | 11.57 | 13 | 52943 | 42951 | 50509217 |
Drug reaction with eosinophilia and systemic symptoms | 15.83 | 11.57 | 5 | 52951 | 28419 | 50523749 |
Parkinsonism | 15.73 | 11.57 | 31 | 52925 | 8816 | 50543352 |
Blood pressure fluctuation | 15.65 | 11.57 | 9 | 52947 | 35814 | 50516354 |
Enteritis | 15.57 | 11.57 | 27 | 52929 | 6968 | 50545200 |
Therapeutic response decreased | 15.39 | 11.57 | 16 | 52940 | 47215 | 50504953 |
Pancreatic carcinoma recurrent | 15.35 | 11.57 | 5 | 52951 | 78 | 50552090 |
Pregnancy | 15.11 | 11.57 | 6 | 52950 | 29571 | 50522597 |
Chills | 15 | 11.57 | 161 | 52795 | 96526 | 50455642 |
Oesophagitis | 14.95 | 11.57 | 39 | 52917 | 13344 | 50538824 |
Intentional self-injury | 14.93 | 11.57 | 3 | 52953 | 23109 | 50529059 |
Ovarian cancer recurrent | 14.75 | 11.57 | 10 | 52946 | 872 | 50551296 |
Haematocrit decreased | 14.71 | 11.57 | 74 | 52882 | 34902 | 50517266 |
Hypermagnesaemia | 14.63 | 11.57 | 10 | 52946 | 884 | 50551284 |
Dyssomnia | 14.48 | 11.57 | 4 | 52952 | 34 | 50552134 |
Dyspepsia | 14.23 | 11.57 | 129 | 52827 | 73968 | 50478200 |
Asthma | 14.19 | 11.57 | 47 | 52909 | 89290 | 50462878 |
Bacteraemia | 14.07 | 11.57 | 40 | 52916 | 14393 | 50537775 |
Acute myeloid leukaemia | 13.94 | 11.57 | 41 | 52915 | 15033 | 50537135 |
Ascites | 13.79 | 11.57 | 74 | 52882 | 35787 | 50516381 |
Hypomagnesaemia | 13.51 | 11.57 | 54 | 52902 | 23102 | 50529066 |
Heart rate decreased | 13.51 | 11.57 | 11 | 52945 | 36486 | 50515682 |
Diabetes mellitus | 13.45 | 11.57 | 19 | 52937 | 49014 | 50503154 |
Lymph node pain | 13.39 | 11.57 | 11 | 52945 | 1284 | 50550884 |
Cataract | 13.32 | 11.57 | 90 | 52866 | 47210 | 50504958 |
Systemic inflammatory response syndrome | 13.26 | 11.57 | 21 | 52935 | 5028 | 50547140 |
Embolism | 13.10 | 11.57 | 25 | 52931 | 6943 | 50545225 |
Inflammation | 12.87 | 11.57 | 25 | 52931 | 56887 | 50495281 |
Alopecia | 12.78 | 11.57 | 180 | 52776 | 244867 | 50307301 |
Dizziness | 12.66 | 11.57 | 462 | 52494 | 345907 | 50206261 |
Plasmacytoma | 12.64 | 11.57 | 14 | 52942 | 2371 | 50549797 |
Dysphagia | 12.45 | 11.57 | 130 | 52826 | 77388 | 50474780 |
Palpitations | 12.25 | 11.57 | 152 | 52804 | 94354 | 50457814 |
Urinary tract infection | 12.25 | 11.57 | 314 | 52642 | 223706 | 50328462 |
Enterocolitis infectious | 12.13 | 11.57 | 11 | 52945 | 1467 | 50550701 |
Wrong technique in product usage process | 12.02 | 11.57 | 25 | 52931 | 55485 | 50496683 |
Stomatitis | 11.88 | 11.57 | 160 | 52796 | 101184 | 50450984 |
Non-small cell lung cancer | 11.85 | 11.57 | 15 | 52941 | 2922 | 50549246 |
Gastrointestinal injury | 11.74 | 11.57 | 7 | 52949 | 488 | 50551680 |
Osteoporosis | 11.71 | 11.57 | 18 | 52938 | 44861 | 50507307 |
Neutropenic sepsis | 11.70 | 11.57 | 37 | 52919 | 14110 | 50538058 |
Sedation | 11.61 | 11.57 | 9 | 52947 | 30601 | 50521567 |
Lethargy | 11.59 | 11.57 | 90 | 52866 | 49342 | 50502826 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 355.41 | 12.47 | 535 | 33626 | 111705 | 29428661 |
Fatigue | 194.44 | 12.47 | 800 | 33361 | 316021 | 29224345 |
Plasma cell myeloma | 184.77 | 12.47 | 221 | 33940 | 36894 | 29503472 |
Disease progression | 135.66 | 12.47 | 295 | 33866 | 81621 | 29458745 |
Nausea | 134.81 | 12.47 | 674 | 33487 | 288581 | 29251785 |
Dehydration | 128.02 | 12.47 | 355 | 33806 | 114393 | 29425973 |
Death | 101.51 | 12.47 | 708 | 33453 | 341376 | 29198990 |
Malignant neoplasm progression | 98.09 | 12.47 | 244 | 33917 | 73615 | 29466751 |
Diarrhoea | 95.99 | 12.47 | 684 | 33477 | 332014 | 29208352 |
Pneumonia | 91.60 | 12.47 | 657 | 33504 | 319515 | 29220851 |
Vomiting | 90.50 | 12.47 | 483 | 33678 | 211777 | 29328589 |
Decreased appetite | 84.59 | 12.47 | 362 | 33799 | 144980 | 29395386 |
Drug abuse | 72.81 | 12.47 | 5 | 34156 | 79878 | 29460488 |
Drug interaction | 69.95 | 12.47 | 75 | 34086 | 197310 | 29343056 |
White blood cell count decreased | 68.58 | 12.47 | 232 | 33929 | 83130 | 29457236 |
Drug ineffective | 64.14 | 12.47 | 211 | 33950 | 362959 | 29177407 |
Toxicity to various agents | 63.75 | 12.47 | 64 | 34097 | 173597 | 29366769 |
Neuropathy peripheral | 58.69 | 12.47 | 198 | 33963 | 70829 | 29469537 |
Full blood count decreased | 57.26 | 12.47 | 81 | 34080 | 15911 | 29524455 |
Constipation | 55.64 | 12.47 | 270 | 33891 | 113890 | 29426476 |
Condition aggravated | 54.73 | 12.47 | 53 | 34108 | 146242 | 29394124 |
Platelet count decreased | 50.59 | 12.47 | 247 | 33914 | 104425 | 29435941 |
Completed suicide | 48.12 | 12.47 | 22 | 34139 | 90224 | 29450142 |
Meconium abnormal | 43.94 | 12.47 | 11 | 34150 | 54 | 29540312 |
Neutropenia | 43.80 | 12.47 | 281 | 33880 | 131430 | 29408936 |
Neutrophil count decreased | 40.98 | 12.47 | 127 | 34034 | 43440 | 29496926 |
Overdose | 40.20 | 12.47 | 21 | 34140 | 79798 | 29460568 |
Hospice care | 38.95 | 12.47 | 38 | 34123 | 5030 | 29535336 |
Rash | 38.06 | 12.47 | 360 | 33801 | 189459 | 29350907 |
Neoplasm progression | 37.78 | 12.47 | 73 | 34088 | 18539 | 29521827 |
Failure to thrive | 36.95 | 12.47 | 45 | 34116 | 7639 | 29532727 |
Small intestinal obstruction | 36.58 | 12.47 | 59 | 34102 | 13002 | 29527364 |
Cytokine release syndrome | 35.03 | 12.47 | 58 | 34103 | 13061 | 29527305 |
Back pain | 32.61 | 12.47 | 216 | 33945 | 102068 | 29438298 |
Necrotising enterocolitis neonatal | 31.15 | 12.47 | 11 | 34150 | 200 | 29540166 |
Deep vein thrombosis | 31.02 | 12.47 | 140 | 34021 | 57259 | 29483107 |
Product use in unapproved indication | 30.71 | 12.47 | 33 | 34128 | 86842 | 29453524 |
Asthenia | 30.51 | 12.47 | 381 | 33780 | 214869 | 29325497 |
Therapeutic product effect incomplete | 29.39 | 12.47 | 5 | 34156 | 39300 | 29501066 |
Intentional overdose | 28.60 | 12.47 | 5 | 34156 | 38523 | 29501843 |
Muscle spasms | 28.19 | 12.47 | 149 | 34012 | 64933 | 29475433 |
Sepsis | 27.76 | 12.47 | 269 | 33892 | 142413 | 29397953 |
Coma | 25.48 | 12.47 | 7 | 34154 | 39443 | 29500923 |
Bradycardia | 25.42 | 12.47 | 23 | 34138 | 65606 | 29474760 |
Adverse drug reaction | 25.40 | 12.47 | 73 | 34088 | 23947 | 29516419 |
Rhabdomyolysis | 25.15 | 12.47 | 20 | 34141 | 60788 | 29479578 |
Intentional product misuse | 24.65 | 12.47 | 5 | 34156 | 34656 | 29505710 |
Suicide attempt | 24.10 | 12.47 | 5 | 34156 | 34105 | 29506261 |
Off label use | 24.04 | 12.47 | 227 | 33934 | 300573 | 29239793 |
Thrombosis | 24.01 | 12.47 | 106 | 34055 | 42939 | 29497427 |
Pulmonary embolism | 24 | 12.47 | 161 | 34000 | 76373 | 29463993 |
General physical health deterioration | 23.91 | 12.47 | 52 | 34109 | 102805 | 29437561 |
Ageusia | 23.17 | 12.47 | 39 | 34122 | 8899 | 29531467 |
Injection site pain | 22.42 | 12.47 | 5 | 34156 | 32441 | 29507925 |
Cardiac failure | 21.09 | 12.47 | 37 | 34124 | 79250 | 29461116 |
Laboratory test abnormal | 20.93 | 12.47 | 57 | 34104 | 18128 | 29522238 |
Hiccups | 20.82 | 12.47 | 37 | 34124 | 8816 | 29531550 |
Oral pain | 20.74 | 12.47 | 38 | 34123 | 9269 | 29531097 |
Spinal cord compression | 20.60 | 12.47 | 23 | 34138 | 3559 | 29536807 |
Dysgeusia | 20.30 | 12.47 | 65 | 34096 | 22609 | 29517757 |
Psoriasis | 20.29 | 12.47 | 6 | 34155 | 32221 | 29508145 |
Coronary artery disease | 20.28 | 12.47 | 13 | 34148 | 44177 | 29496189 |
Hyponatraemia | 19.85 | 12.47 | 140 | 34021 | 67493 | 29472873 |
Bacteraemia | 19.62 | 12.47 | 52 | 34109 | 16271 | 29524095 |
Wrong technique in product usage process | 19.52 | 12.47 | 6 | 34155 | 31422 | 29508944 |
Fluid imbalance | 19.11 | 12.47 | 8 | 34153 | 234 | 29540132 |
C-reactive protein increased | 19.01 | 12.47 | 14 | 34147 | 44249 | 29496117 |
Rheumatoid arthritis | 18.47 | 12.47 | 7 | 34154 | 32145 | 29508221 |
Weight decreased | 18.38 | 12.47 | 260 | 33901 | 150645 | 29389721 |
Treatment failure | 18.18 | 12.47 | 10 | 34151 | 36929 | 29503437 |
Pleural effusion | 17.26 | 12.47 | 142 | 34019 | 71766 | 29468600 |
Hypophagia | 17.04 | 12.47 | 58 | 34103 | 20814 | 29519552 |
Drug reaction with eosinophilia and systemic symptoms | 16.24 | 12.47 | 6 | 34155 | 27986 | 29512380 |
Diaphragmatic rupture | 16.08 | 12.47 | 4 | 34157 | 19 | 29540347 |
Clostridium difficile infection | 16.05 | 12.47 | 48 | 34113 | 16093 | 29524273 |
Dystonia | 15.96 | 12.47 | 35 | 34126 | 9714 | 29530652 |
Bacillus bacteraemia | 15.85 | 12.47 | 5 | 34156 | 63 | 29540303 |
Mental status changes | 15.83 | 12.47 | 81 | 34080 | 34846 | 29505520 |
Inappropriate schedule of product administration | 15.59 | 12.47 | 17 | 34144 | 44455 | 29495911 |
Plasma cell myeloma recurrent | 15.21 | 12.47 | 20 | 34141 | 3663 | 29536703 |
Anaemia | 14.98 | 12.47 | 320 | 33841 | 200631 | 29339735 |
Mixed dementia | 14.92 | 12.47 | 7 | 34154 | 270 | 29540096 |
Laparotomy | 14.85 | 12.47 | 7 | 34154 | 273 | 29540093 |
Inferior vena caval occlusion | 14.77 | 12.47 | 4 | 34157 | 28 | 29540338 |
Immune effector cell-associated neurotoxicity syndrome | 14.76 | 12.47 | 13 | 34148 | 1511 | 29538855 |
Oesophagitis | 14.35 | 12.47 | 38 | 34123 | 11885 | 29528481 |
Haematochezia | 14.27 | 12.47 | 13 | 34148 | 36970 | 29503396 |
Temperature intolerance | 13.87 | 12.47 | 17 | 34144 | 2904 | 29537462 |
Peripheral swelling | 13.79 | 12.47 | 123 | 34038 | 63616 | 29476750 |
Cholestasis | 13.66 | 12.47 | 5 | 34156 | 23457 | 29516909 |
Red blood cell count decreased | 13.49 | 12.47 | 62 | 34099 | 25540 | 29514826 |
Abdominal distension | 13.44 | 12.47 | 95 | 34066 | 45816 | 29494550 |
Pancytopenia | 13.40 | 12.47 | 151 | 34010 | 83017 | 29457349 |
Pneumonitis | 13.38 | 12.47 | 66 | 34095 | 27978 | 29512388 |
Hypoxia | 13.27 | 12.47 | 97 | 34064 | 47282 | 29493084 |
Wrist deformity | 13.25 | 12.47 | 7 | 34154 | 349 | 29540017 |
Cholangiocarcinoma | 13.20 | 12.47 | 10 | 34151 | 940 | 29539426 |
Therapeutic response decreased | 13.19 | 12.47 | 6 | 34155 | 24705 | 29515661 |
Seizure | 13.17 | 12.47 | 59 | 34102 | 93064 | 29447302 |
Tooth disorder | 13.16 | 12.47 | 32 | 34129 | 9497 | 29530869 |
Blood potassium decreased | 13.09 | 12.47 | 44 | 34117 | 15690 | 29524676 |
Therapeutic product effect decreased | 13.06 | 12.47 | 9 | 34152 | 29442 | 29510924 |
Drug dependence | 13.04 | 12.47 | 4 | 34157 | 20977 | 29519389 |
Oral candidiasis | 12.73 | 12.47 | 34 | 34127 | 10688 | 29529678 |
Myocardial infarction | 12.70 | 12.47 | 75 | 34086 | 110221 | 29430145 |
Respiratory arrest | 12.70 | 12.47 | 7 | 34154 | 25826 | 29514540 |
Enterocolitis infectious | 12.49 | 12.47 | 11 | 34150 | 1278 | 29539088 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 739.58 | 11.25 | 958 | 68449 | 186699 | 64242626 |
Disease progression | 322.24 | 11.25 | 560 | 68847 | 141120 | 64288205 |
Dehydration | 316.34 | 11.25 | 711 | 68696 | 216052 | 64213273 |
Plasma cell myeloma | 279.32 | 11.25 | 294 | 69113 | 45781 | 64383544 |
Nausea | 250.30 | 11.25 | 1569 | 67838 | 784231 | 63645094 |
Drug ineffective | 230.03 | 11.25 | 344 | 69063 | 839903 | 63589422 |
Vomiting | 229.48 | 11.25 | 1183 | 68224 | 549934 | 63879391 |
Fatigue | 227.14 | 11.25 | 1477 | 67930 | 747253 | 63682072 |
Diarrhoea | 225.53 | 11.25 | 1436 | 67971 | 721268 | 63708057 |
White blood cell count decreased | 213.75 | 11.25 | 503 | 68904 | 157334 | 64271991 |
Platelet count decreased | 147.69 | 11.25 | 456 | 68951 | 167255 | 64262070 |
Toxicity to various agents | 142.19 | 11.25 | 110 | 69297 | 363403 | 64065922 |
Malignant neoplasm progression | 141.20 | 11.25 | 349 | 69058 | 112522 | 64316803 |
Death | 120.22 | 11.25 | 909 | 68498 | 481796 | 63947529 |
Pneumonia | 116.25 | 11.25 | 1011 | 68396 | 558565 | 63870760 |
Decreased appetite | 114.55 | 11.25 | 601 | 68806 | 280688 | 64148637 |
Neutropenia | 112.42 | 11.25 | 533 | 68874 | 239091 | 64190234 |
Constipation | 111.90 | 11.25 | 516 | 68891 | 228821 | 64200504 |
Drug abuse | 108.72 | 11.25 | 9 | 69398 | 132365 | 64296960 |
Neoplasm progression | 102.31 | 11.25 | 169 | 69238 | 40795 | 64388530 |
Contraindicated product administered | 102.16 | 11.25 | 3 | 69404 | 107826 | 64321499 |
Neutrophil count decreased | 100.01 | 11.25 | 242 | 69165 | 76954 | 64352371 |
Completed suicide | 99.58 | 11.25 | 59 | 69348 | 224355 | 64204970 |
Synovitis | 93.00 | 11.25 | 3 | 69404 | 99087 | 64330238 |
Asthenia | 91.67 | 11.25 | 779 | 68628 | 427265 | 64002060 |
Small intestinal obstruction | 84.25 | 11.25 | 115 | 69292 | 23458 | 64405867 |
Condition aggravated | 81.97 | 11.25 | 174 | 69233 | 372252 | 64057073 |
Cytokine release syndrome | 78.07 | 11.25 | 104 | 69303 | 20725 | 64408600 |
Failure to thrive | 76.98 | 11.25 | 74 | 69333 | 10330 | 64418995 |
Arthropathy | 76.65 | 11.25 | 18 | 69389 | 120949 | 64308376 |
Blood magnesium decreased | 75.92 | 11.25 | 84 | 69323 | 13821 | 64415504 |
Therapeutic product effect decreased | 75.43 | 11.25 | 16 | 69391 | 115335 | 64313990 |
Full blood count decreased | 74.48 | 11.25 | 106 | 69301 | 22476 | 64406849 |
Therapeutic product effect incomplete | 72.69 | 11.25 | 12 | 69395 | 103470 | 64325855 |
Abdominal pain | 71.86 | 11.25 | 578 | 68829 | 311797 | 64117528 |
Hospice care | 71.61 | 11.25 | 62 | 69345 | 7563 | 64421762 |
Sepsis | 70.77 | 11.25 | 457 | 68950 | 229884 | 64199441 |
Thrombosis | 70.57 | 11.25 | 201 | 69206 | 70441 | 64358884 |
Drug interaction | 68.65 | 11.25 | 183 | 69224 | 361900 | 64067425 |
Pleural effusion | 68.61 | 11.25 | 294 | 69113 | 126265 | 64303060 |
Neovascularisation | 68.09 | 11.25 | 30 | 69377 | 1073 | 64428252 |
Joint swelling | 66.84 | 11.25 | 80 | 69327 | 215302 | 64214023 |
Off label use | 66.07 | 11.25 | 405 | 69002 | 632401 | 63796924 |
Clostridium difficile infection | 64.57 | 11.25 | 129 | 69278 | 36034 | 64393291 |
Coma | 64.19 | 11.25 | 9 | 69398 | 87606 | 64341719 |
Neuropathy peripheral | 58.38 | 11.25 | 266 | 69141 | 117259 | 64312066 |
Systemic lupus erythematosus | 56.79 | 11.25 | 8 | 69399 | 77604 | 64351721 |
Intentional overdose | 55.77 | 11.25 | 14 | 69393 | 89930 | 64339395 |
Injection site pain | 55.76 | 11.25 | 25 | 69382 | 111383 | 64317942 |
Heart rate abnormal | 53.58 | 11.25 | 44 | 69363 | 4991 | 64424334 |
General physical health deterioration | 53.34 | 11.25 | 86 | 69321 | 204339 | 64224986 |
Overdose | 53.06 | 11.25 | 56 | 69351 | 159510 | 64269815 |
Hyponatraemia | 49.05 | 11.25 | 300 | 69107 | 148039 | 64281286 |
Pancytopenia | 48.77 | 11.25 | 292 | 69115 | 143017 | 64286308 |
Carbohydrate antigen 125 increased | 46.95 | 11.25 | 28 | 69379 | 1900 | 64427425 |
Thrombocytopenia | 45.50 | 11.25 | 403 | 69004 | 223398 | 64205927 |
Hair colour changes | 44.84 | 11.25 | 35 | 69372 | 3692 | 64425633 |
Colitis | 44.73 | 11.25 | 152 | 69255 | 58522 | 64370803 |
Pneumonitis | 44.29 | 11.25 | 137 | 69270 | 50228 | 64379097 |
Akathisia | 43.95 | 11.25 | 58 | 69349 | 11452 | 64417873 |
Drug intolerance | 43.70 | 11.25 | 85 | 69322 | 187907 | 64241418 |
Palmar-plantar erythrodysaesthesia syndrome | 42.39 | 11.25 | 95 | 69312 | 28724 | 64400601 |
Lymphadenitis | 42.23 | 11.25 | 34 | 69373 | 3751 | 64425574 |
Suicide attempt | 42.23 | 11.25 | 12 | 69395 | 70995 | 64358330 |
Pulmonary embolism | 41.65 | 11.25 | 285 | 69122 | 146071 | 64283254 |
Deep vein thrombosis | 41.50 | 11.25 | 223 | 69184 | 104959 | 64324366 |
Back pain | 41.24 | 11.25 | 431 | 68976 | 249740 | 64179585 |
Red blood cell count decreased | 41.06 | 11.25 | 130 | 69277 | 48256 | 64381069 |
Hypophagia | 39.87 | 11.25 | 113 | 69294 | 39474 | 64389851 |
Rheumatoid arthritis | 39.30 | 11.25 | 73 | 69334 | 164221 | 64265104 |
Gangrene | 37.78 | 11.25 | 43 | 69364 | 7295 | 64422030 |
Oral pain | 37.54 | 11.25 | 88 | 69319 | 27405 | 64401920 |
Anaemia | 37.22 | 11.25 | 593 | 68814 | 378087 | 64051238 |
Weight decreased | 36.25 | 11.25 | 468 | 68939 | 285271 | 64144054 |
Arterial occlusive disease | 35.85 | 11.25 | 41 | 69366 | 6992 | 64422333 |
Dysgeusia | 35.09 | 11.25 | 121 | 69286 | 46926 | 64382399 |
Intentional product misuse | 34.97 | 11.25 | 17 | 69390 | 72278 | 64357047 |
C-reactive protein increased | 34.21 | 11.25 | 31 | 69376 | 94878 | 64334447 |
Pyrexia | 33.91 | 11.25 | 813 | 68594 | 557831 | 63871494 |
Mental status changes | 33.05 | 11.25 | 142 | 69265 | 61020 | 64368305 |
Lower respiratory tract infection | 32.81 | 11.25 | 32 | 69375 | 94582 | 64334743 |
Nasopharyngitis | 32.80 | 11.25 | 105 | 69302 | 195968 | 64233357 |
Coronary artery disease | 32.77 | 11.25 | 12 | 69395 | 60421 | 64368904 |
Bacteraemia | 32.33 | 11.25 | 82 | 69325 | 26829 | 64402496 |
Injection site erythema | 32.24 | 11.25 | 18 | 69389 | 70782 | 64358543 |
Hypoxia | 32.17 | 11.25 | 183 | 69224 | 87966 | 64341359 |
Alopecia areata | 31.62 | 11.25 | 20 | 69387 | 1508 | 64427817 |
Injection site reaction | 31.48 | 11.25 | 6 | 69401 | 46658 | 64382667 |
Pericarditis | 31.32 | 11.25 | 14 | 69393 | 62502 | 64366823 |
Haemoglobin decreased | 31.15 | 11.25 | 334 | 69073 | 194729 | 64234596 |
Drug reaction with eosinophilia and systemic symptoms | 30.72 | 11.25 | 10 | 69397 | 54207 | 64375118 |
Mucosal inflammation | 30.57 | 11.25 | 141 | 69266 | 62443 | 64366882 |
Oesophagitis | 30.37 | 11.25 | 70 | 69337 | 21560 | 64407765 |
Rectal cancer metastatic | 30.29 | 11.25 | 13 | 69394 | 436 | 64428889 |
Blood potassium decreased | 30.21 | 11.25 | 104 | 69303 | 40295 | 64389030 |
Hair texture abnormal | 29.38 | 11.25 | 25 | 69382 | 2979 | 64426346 |
Musculoskeletal stiffness | 27.51 | 11.25 | 57 | 69350 | 123149 | 64306176 |
Hepatic enzyme increased | 27.45 | 11.25 | 62 | 69345 | 129881 | 64299444 |
Rhabdomyolysis | 27.45 | 11.25 | 35 | 69372 | 91691 | 64337634 |
Dry skin | 27.04 | 11.25 | 118 | 69289 | 51043 | 64378282 |
Bradycardia | 26.98 | 11.25 | 54 | 69353 | 118165 | 64311160 |
Blood pressure fluctuation | 26.97 | 11.25 | 11 | 69396 | 51860 | 64377465 |
Injection site swelling | 26.49 | 11.25 | 6 | 69401 | 41347 | 64387978 |
Psoriatic arthropathy | 26.32 | 11.25 | 7 | 69400 | 43274 | 64386051 |
Immune effector cell-associated neurotoxicity syndrome | 26.21 | 11.25 | 22 | 69385 | 2573 | 64426752 |
Enterocolitis infectious | 25.11 | 11.25 | 21 | 69386 | 2443 | 64426882 |
Glossodynia | 24.69 | 11.25 | 20 | 69387 | 64676 | 64364649 |
Cardiac failure | 23.47 | 11.25 | 69 | 69338 | 132304 | 64297021 |
Eosinophilia | 23.46 | 11.25 | 6 | 69401 | 38070 | 64391255 |
Red blood cell sedimentation rate increased | 23.37 | 11.25 | 3 | 69404 | 31232 | 64398093 |
Red cell distribution width increased | 23.29 | 11.25 | 45 | 69362 | 12264 | 64417061 |
Weight increased | 22.96 | 11.25 | 135 | 69272 | 213213 | 64216112 |
Hypokalaemia | 22.95 | 11.25 | 216 | 69191 | 121687 | 64307638 |
Swelling | 22.67 | 11.25 | 92 | 69315 | 160126 | 64269199 |
Non-small cell lung cancer | 22.42 | 11.25 | 27 | 69380 | 4863 | 64424462 |
Folliculitis | 22.24 | 11.25 | 3 | 69404 | 30074 | 64399251 |
Paradoxical drug reaction | 22.08 | 11.25 | 30 | 69377 | 6090 | 64423235 |
Discomfort | 22.05 | 11.25 | 33 | 69374 | 80845 | 64348480 |
Performance status decreased | 21.99 | 11.25 | 28 | 69379 | 5336 | 64423989 |
Hepatitis | 21.62 | 11.25 | 11 | 69396 | 45571 | 64383754 |
Mobility decreased | 21.54 | 11.25 | 37 | 69370 | 85803 | 64343522 |
Cholestasis of pregnancy | 21.40 | 11.25 | 13 | 69394 | 912 | 64428413 |
Systemic inflammatory response syndrome | 21.33 | 11.25 | 39 | 69368 | 10196 | 64419129 |
Hypersensitivity | 21.31 | 11.25 | 124 | 69283 | 196328 | 64232997 |
Infusion related reaction | 21.10 | 11.25 | 98 | 69309 | 164369 | 64264956 |
Heart rate decreased | 21.04 | 11.25 | 17 | 69390 | 55050 | 64374275 |
Taste disorder | 21.01 | 11.25 | 37 | 69370 | 9396 | 64419929 |
Muscle twitching | 20.88 | 11.25 | 56 | 69351 | 18942 | 64410383 |
Ageusia | 20.84 | 11.25 | 46 | 69361 | 13767 | 64415558 |
Cytomegalovirus infection | 20.83 | 11.25 | 7 | 69400 | 37192 | 64392133 |
Treatment failure | 20.63 | 11.25 | 61 | 69346 | 116755 | 64312570 |
Pain | 20.48 | 11.25 | 447 | 68960 | 553064 | 63876261 |
Asthma | 20.46 | 11.25 | 45 | 69362 | 95180 | 64334145 |
Enteritis | 20.27 | 11.25 | 42 | 69365 | 12035 | 64417290 |
Wound | 20.09 | 11.25 | 32 | 69375 | 76445 | 64352880 |
Madarosis | 19.99 | 11.25 | 18 | 69389 | 2312 | 64427013 |
Psoriasis | 19.80 | 11.25 | 29 | 69378 | 71674 | 64357651 |
Sedation | 19.67 | 11.25 | 10 | 69397 | 41452 | 64387873 |
Medication error | 19.63 | 11.25 | 15 | 69392 | 49951 | 64379374 |
Blood creatine increased | 19.38 | 11.25 | 33 | 69374 | 8159 | 64421166 |
Hypermagnesaemia | 19.37 | 11.25 | 13 | 69394 | 1084 | 64428241 |
Streptococcal bacteraemia | 19.34 | 11.25 | 20 | 69387 | 3047 | 64426278 |
Blood pressure systolic increased | 19.23 | 11.25 | 15 | 69392 | 49438 | 64379887 |
Wrong technique in product usage process | 19.22 | 11.25 | 25 | 69382 | 64949 | 64364376 |
Intentional self-injury | 19.04 | 11.25 | 4 | 69403 | 29040 | 64400285 |
Metastatic renal cell carcinoma | 18.91 | 11.25 | 17 | 69390 | 2179 | 64427146 |
Hypophosphataemia | 18.89 | 11.25 | 46 | 69361 | 14674 | 64414651 |
Product use in unapproved indication | 18.87 | 11.25 | 112 | 69295 | 176506 | 64252819 |
Embolism | 18.75 | 11.25 | 41 | 69366 | 12194 | 64417131 |
Loss of personal independence in daily activities | 18.39 | 11.25 | 31 | 69376 | 72423 | 64356902 |
Klebsiella bacteraemia | 17.99 | 11.25 | 17 | 69390 | 2323 | 64427002 |
Lymphocyte count decreased | 17.92 | 11.25 | 89 | 69318 | 40610 | 64388715 |
Depressed level of consciousness | 17.90 | 11.25 | 38 | 69369 | 81398 | 64347927 |
Haematocrit decreased | 17.70 | 11.25 | 110 | 69297 | 54545 | 64374780 |
Therapeutic response decreased | 17.69 | 11.25 | 18 | 69389 | 52170 | 64377155 |
Dysphagia | 17.55 | 11.25 | 184 | 69223 | 106628 | 64322697 |
Inflammation | 17.46 | 11.25 | 27 | 69380 | 65273 | 64364052 |
Stomatitis | 17.17 | 11.25 | 187 | 69220 | 109418 | 64319907 |
Cancer pain | 17.10 | 11.25 | 22 | 69385 | 4235 | 64425090 |
Cholestasis | 16.96 | 11.25 | 14 | 69393 | 44858 | 64384467 |
Injection site bruising | 16.92 | 11.25 | 9 | 69398 | 36364 | 64392961 |
Injection site pruritus | 16.67 | 11.25 | 10 | 69397 | 37816 | 64391509 |
Acquired cystic kidney disease | 16.65 | 11.25 | 5 | 69402 | 57 | 64429268 |
Dizziness | 16.40 | 11.25 | 591 | 68816 | 429572 | 63999753 |
Ill-defined disorder | 16.34 | 11.25 | 14 | 69393 | 44038 | 64385287 |
Cholangitis | 16.32 | 11.25 | 36 | 69371 | 10766 | 64418559 |
Autoimmune nephritis | 16.13 | 11.25 | 9 | 69398 | 538 | 64428787 |
Clostridium difficile colitis | 16.11 | 11.25 | 65 | 69342 | 27158 | 64402167 |
Arthralgia | 16.09 | 11.25 | 358 | 69049 | 441902 | 63987423 |
Osteoporosis | 16.07 | 11.25 | 13 | 69394 | 42067 | 64387258 |
Hypoglycaemia | 15.83 | 11.25 | 47 | 69360 | 89845 | 64339480 |
Retching | 15.80 | 11.25 | 44 | 69363 | 15212 | 64414113 |
Product use issue | 15.79 | 11.25 | 97 | 69310 | 151618 | 64277707 |
Exposure during pregnancy | 15.65 | 11.25 | 38 | 69369 | 77637 | 64351688 |
Impaired healing | 15.23 | 11.25 | 26 | 69381 | 60447 | 64368878 |
Fluid imbalance | 15.19 | 11.25 | 8 | 69399 | 426 | 64428899 |
Mixed dementia | 15.09 | 11.25 | 7 | 69400 | 283 | 64429042 |
Drug hypersensitivity | 14.94 | 11.25 | 348 | 69059 | 237467 | 64191858 |
Spinal cord compression | 14.87 | 11.25 | 24 | 69383 | 5679 | 64423646 |
Anaphylactic shock | 14.86 | 11.25 | 7 | 69400 | 30321 | 64399004 |
Lymph node pain | 14.78 | 11.25 | 12 | 69395 | 1340 | 64427985 |
Diabetes mellitus | 14.62 | 11.25 | 31 | 69376 | 66443 | 64362882 |
Dystonia | 14.48 | 11.25 | 49 | 69358 | 18816 | 64410509 |
Inferior vena caval occlusion | 14.48 | 11.25 | 4 | 69403 | 33 | 64429292 |
Therapeutic drug monitoring analysis incorrectly performed | 14.42 | 11.25 | 6 | 69401 | 186 | 64429139 |
Gastric disorder | 14.42 | 11.25 | 66 | 69341 | 29131 | 64400194 |
Stress | 14.37 | 11.25 | 27 | 69380 | 60507 | 64368818 |
Tumour marker increased | 14.13 | 11.25 | 18 | 69389 | 3432 | 64425893 |
Respiratory arrest | 14.08 | 11.25 | 22 | 69385 | 52963 | 64376362 |
Hyperglycaemia | 14.06 | 11.25 | 113 | 69294 | 60855 | 64368470 |
Feeding disorder | 14.06 | 11.25 | 38 | 69369 | 12911 | 64416414 |
Diabetes mellitus inadequate control | 13.84 | 11.25 | 3 | 69404 | 21318 | 64408007 |
Pancreatic carcinoma recurrent | 13.70 | 11.25 | 5 | 69402 | 108 | 64429217 |
Cardiogenic shock | 13.70 | 11.25 | 9 | 69398 | 32418 | 64396907 |
Inappropriate schedule of product administration | 13.68 | 11.25 | 52 | 69355 | 92234 | 64337091 |
Renal cell carcinoma | 13.67 | 11.25 | 24 | 69383 | 6080 | 64423245 |
Arthritis infective | 13.67 | 11.25 | 26 | 69381 | 7004 | 64422321 |
Hypoalbuminaemia | 13.65 | 11.25 | 46 | 69361 | 17628 | 64411697 |
Bacillus bacteraemia | 13.53 | 11.25 | 5 | 69402 | 112 | 64429213 |
Skull fracture | 13.41 | 11.25 | 12 | 69395 | 1529 | 64427796 |
Oral candidiasis | 13.40 | 11.25 | 55 | 69352 | 23157 | 64406168 |
Myocardial infarction | 13.39 | 11.25 | 114 | 69293 | 165707 | 64263618 |
Mean cell haemoglobin concentration decreased | 13.20 | 11.25 | 18 | 69389 | 3666 | 64425659 |
Agranulocytosis | 13.17 | 11.25 | 13 | 69394 | 38216 | 64391109 |
Muscle spasms | 13.12 | 11.25 | 219 | 69188 | 140804 | 64288521 |
Abdominal infection | 13.10 | 11.25 | 16 | 69391 | 2924 | 64426401 |
Drug dependence | 13.09 | 11.25 | 10 | 69397 | 33302 | 64396023 |
Multiple sclerosis relapse | 13.04 | 11.25 | 15 | 69392 | 41120 | 64388205 |
Colon cancer metastatic | 12.96 | 11.25 | 13 | 69394 | 1910 | 64427415 |
Atrial fibrillation | 12.87 | 11.25 | 257 | 69150 | 170832 | 64258493 |
Pancreatic carcinoma | 12.87 | 11.25 | 32 | 69375 | 10341 | 64418984 |
Fear | 12.77 | 11.25 | 3 | 69404 | 20168 | 64409157 |
Acute myeloid leukaemia | 12.77 | 11.25 | 61 | 69346 | 27402 | 64401923 |
Hiccups | 12.75 | 11.25 | 28 | 69379 | 8348 | 64420977 |
Lymphadenopathy | 12.72 | 11.25 | 90 | 69317 | 46596 | 64382729 |
Therapy non-responder | 12.68 | 11.25 | 33 | 69374 | 65866 | 64363459 |
Irritable bowel syndrome | 12.54 | 11.25 | 13 | 69394 | 37356 | 64391969 |
Skin exfoliation | 12.51 | 11.25 | 87 | 69320 | 44798 | 64384527 |
Urinary tract infection | 12.49 | 11.25 | 332 | 69075 | 231264 | 64198061 |
Metastases to liver | 12.48 | 11.25 | 55 | 69352 | 23886 | 64405439 |
Pancreatic carcinoma metastatic | 12.47 | 11.25 | 17 | 69390 | 3461 | 64425864 |
Aggression | 12.47 | 11.25 | 19 | 69388 | 46213 | 64383112 |
Cholangiocarcinoma | 12.44 | 11.25 | 13 | 69394 | 2005 | 64427320 |
Maternal exposure during pregnancy | 12.37 | 11.25 | 57 | 69350 | 95827 | 64333498 |
Lung squamous cell carcinoma metastatic | 12.32 | 11.25 | 4 | 69403 | 60 | 64429265 |
Haematochezia | 12.20 | 11.25 | 34 | 69373 | 66339 | 64362986 |
Oesophageal ulcer | 12.11 | 11.25 | 23 | 69384 | 6187 | 64423138 |
Obstructive airways disorder | 11.92 | 11.25 | 5 | 69402 | 23180 | 64406145 |
Liver injury | 11.74 | 11.25 | 9 | 69398 | 29923 | 64399402 |
Hypovolaemia | 11.69 | 11.25 | 40 | 69367 | 15446 | 64413879 |
Hypogeusia | 11.66 | 11.25 | 11 | 69396 | 1500 | 64427825 |
Injury | 11.59 | 11.25 | 27 | 69380 | 55965 | 64373360 |
Lymphatic disorder | 11.56 | 11.25 | 6 | 69401 | 310 | 64429015 |
Spasmodic dysphonia | 11.48 | 11.25 | 5 | 69402 | 174 | 64429151 |
Oxygen saturation decreased | 11.42 | 11.25 | 68 | 69339 | 107108 | 64322217 |
Morbid thoughts | 11.39 | 11.25 | 8 | 69399 | 718 | 64428607 |
Fibromyalgia | 11.36 | 11.25 | 13 | 69394 | 35718 | 64393607 |
Drug level increased | 11.36 | 11.25 | 12 | 69395 | 34184 | 64395141 |
Pneumothorax | 11.32 | 11.25 | 54 | 69353 | 24244 | 64405081 |
Chills | 11.28 | 11.25 | 209 | 69198 | 137055 | 64292270 |
Blood sodium decreased | 11.27 | 11.25 | 62 | 69345 | 29420 | 64399905 |
None
Source | Code | Description |
---|---|---|
ATC | N05AB04 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with piperazine structure |
FDA CS | M0016525 | Phenothiazines |
MeSH PA | D000932 | Antiemetics |
MeSH PA | D014150 | Antipsychotic Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D015259 | Dopamine Agents |
MeSH PA | D018492 | Dopamine Antagonists |
MeSH PA | D005765 | Gastrointestinal Agents |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D014149 | Tranquilizing Agents |
CHEBI has role | CHEBI:37890 | alpha-adrenergic receptor blockaders |
CHEBI has role | CHEBI:48561 | dopaminergic antagonists |
CHEBI has role | CHEBI:48873 | acetylcholine receptor antagonist |
CHEBI has role | CHEBI:50919 | antiemetico |
CHEBI has role | CHEBI:65190 | typical antipsychotic drugs |
CHEBI has role | CHEBI:76779 | post-proline endopeptidase inhibitors |
CHEBI has role | CHEBI:131787 | D2R antagonist |
FDA EPC | N0000175746 | Phenothiazine |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Nausea and vomiting | indication | 16932000 | |
Schizophrenia | indication | 58214004 | DOID:5419 |
Nonpsychotic Anxiety | indication | ||
Prolonged-Severe Nausea and Vomiting | indication | ||
Migraine | off-label use | 37796009 | DOID:6364 |
Chemotherapy-induced nausea and vomiting | off-label use | 236084000 | |
Brain damage | contraindication | 2470005 | |
Tachyarrhythmia | contraindication | 6285003 | |
Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
Alcoholism | contraindication | 7200002 | |
Organophosphate poisoning | contraindication | 8260003 | |
Weight gain finding | contraindication | 8943002 | |
Severe chronic ulcerative colitis | contraindication | 14311001 | |
Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
Senile dementia | contraindication | 15662003 | |
Chronic disease of respiratory system | contraindication | 17097001 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Glaucoma | contraindication | 23986001 | DOID:1686 |
Toxic megacolon | contraindication | 28536002 | DOID:1770 |
Orthostatic hypotension | contraindication | 28651003 | |
Atony of colon | contraindication | 29479008 | |
Torsades de pointes | contraindication | 31722008 | |
Parkinsonism | contraindication | 32798002 | |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Complete trisomy 21 syndrome | contraindication | 41040004 | DOID:14250 |
Conduction disorder of the heart | contraindication | 44808001 | |
Achalasia of esophagus | contraindication | 45564002 | DOID:9164 |
Chronic heart failure | contraindication | 48447003 | |
Bradycardia | contraindication | 48867003 | |
Paralytic ileus | contraindication | 55525008 | DOID:8442 |
Peptic reflux disease | contraindication | 57643001 | |
Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
Drug AND/OR toxin-induced diarrhea | contraindication | 65979008 | |
Extrapyramidal disease | contraindication | 76349003 | |
Spastic paralysis | contraindication | 78403003 | |
Disturbance of salivary secretion | contraindication | 78948009 | |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Hiatal hernia | contraindication | 84089009 | DOID:12642 |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Leukopenia | contraindication | 84828003 | DOID:615 |
Stupor | contraindication | 89458003 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Tardive dyskinesia | contraindication | 102449007 | |
Prolonged QT interval | contraindication | 111975006 | |
Gastrointestinal obstruction | contraindication | 126765001 | |
Acute disease of cardiovascular system | contraindication | 128487001 | |
Autonomic dysreflexia | contraindication | 129618003 | |
Bleeding | contraindication | 131148009 | |
Angina pectoris | contraindication | 194828000 | |
Myocardial dysfunction | contraindication | 233928007 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Bladder outflow obstruction | contraindication | 236645006 | |
Metabolic syndrome X | contraindication | 237602007 | DOID:14221 |
Hyperprolactinemia | contraindication | 237662005 | DOID:12700 |
Pyloric obstruction | contraindication | 244815007 | |
Benign prostatic hyperplasia | contraindication | 266569009 | |
Retention of urine | contraindication | 267064002 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Drowsy | contraindication | 271782001 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Coma | contraindication | 371632003 | |
At risk for aspiration | contraindication | 371736008 | |
Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
Visual impairment | contraindication | 397540003 | |
Gastric ulcer | contraindication | 397825006 | DOID:10808 |
Breastfeeding (mother) | contraindication | 413712001 | |
Chronic lung disease | contraindication | 413839001 | |
Disorder of coronary artery | contraindication | 414024009 | |
Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
Obesity | contraindication | 414916001 | DOID:9970 |
Congenital long QT syndrome | contraindication | 442917000 | |
Carcinoma of female breast | contraindication | 447782002 |
Species | Use | Relation |
---|---|---|
Cats | Gastrointestinal disturbances associated with emotional stress | Indication |
Dogs | Gastrointestinal disturbances associated with emotional stress | Indication |
Product | Applicant | Ingredients |
---|---|---|
Darbazine Spansule Capsule No.1 | Zoetis Inc. | 2 |
Darbazine Injectable | Zoetis Inc. | 2 |
Neo-Darbazine Spansule Capsule No.1, Neo-Darbazine Spansule Capsule No.3 | Zoetis Inc. | 3 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.74 | Basic |
pKa2 | 4.74 | Basic |
pKa3 | 2.21 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 8.76 | WOMBAT-PK | CHEMBL | |||
D(3) dopamine receptor | GPCR | ANTAGONIST | Ki | 8.61 | WOMBAT-PK | IUPHAR | |||
Alpha-2A adrenergic receptor | GPCR | Ki | 7.20 | DRUG MATRIX | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 7.64 | DRUG MATRIX | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | Ki | 5.82 | DRUG MATRIX | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 6.21 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 6.40 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.23 | PDSP | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 7.82 | WOMBAT-PK | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 7.19 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 6.91 | WOMBAT-PK | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 6.91 | DRUG MATRIX | |||||
Alpha-1A adrenergic receptor | GPCR | Ki | 7.62 | WOMBAT-PK | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 8.32 | DRUG MATRIX | |||||
Histamine H1 receptor | GPCR | Ki | 7.72 | WOMBAT-PK | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 6.61 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.96 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 6.49 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 6.72 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 6.80 | DRUG MATRIX | |||||
Alpha-2C adrenergic receptor | GPCR | Ki | 7.92 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.86 | DRUG MATRIX | |||||
Cytochrome P450 2D6 | Enzyme | IC50 | 6.52 | DRUG MATRIX | |||||
D(4) dopamine receptor | GPCR | Ki | 7.17 | WOMBAT-PK | |||||
Alpha-1D adrenergic receptor | GPCR | Ki | 7.89 | DRUG MATRIX | |||||
Cytochrome P450 1A2 | Enzyme | IC50 | 5.70 | DRUG MATRIX | |||||
Tyrosine-protein kinase Fyn | Kinase | IC50 | 5.25 | DRUG MATRIX | |||||
Solute carrier family 22 member 1 | Transporter | IC50 | 4.30 | CHEMBL | |||||
D(1A) dopamine receptor | GPCR | Ki | 7.11 | DRUG MATRIX | |||||
Alpha-1B adrenergic receptor | GPCR | Ki | 7.31 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1B | GPCR | Ki | 5.92 | DRUG MATRIX | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 6.38 | DRUG MATRIX | |||||
Alpha-1A adrenergic receptor | GPCR | IC50 | 7.49 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | IC50 | 6.02 | CHEMBL | |||||
5-hydroxytryptamine receptor 4 | GPCR | Ki | 6.71 | DRUG MATRIX | |||||
Pleiotropic ABC efflux transporter of multiple drugs | Transporter | IC50 | 5.77 | CHEMBL |
ID | Source |
---|---|
4018001 | VUID |
N0000146346 | NUI |
D00479 | KEGG_DRUG |
84-02-6 | SECONDARY_CAS_RN |
1257-78-9 | SECONDARY_CAS_RN |
4017999 | VANDF |
4018000 | VANDF |
4018001 | VANDF |
C0033229 | UMLSCUI |
CHEBI:8435 | CHEBI |
P77 | PDB_CHEM_ID |
CHEMBL728 | ChEMBL_ID |
DB00433 | DRUGBANK_ID |
CHEMBL1200587 | ChEMBL_ID |
CHEMBL1314751 | ChEMBL_ID |
CHEMBL1201154 | ChEMBL_ID |
D011346 | MESH_DESCRIPTOR_UI |
4917 | PUBCHEM_CID |
7279 | IUPHAR_LIGAND_ID |
699 | INN_ID |
YHP6YLT61T | UNII |
235739 | RXNORM |
2073 | MMSL |
5361 | MMSL |
5362 | MMSL |
5363 | MMSL |
6416 | MMSL |
6417 | MMSL |
d00355 | MMSL |
001478 | NDDF |
001479 | NDDF |
001480 | NDDF |
003466 | NDDF |
22827004 | SNOMEDCT_US |
372853006 | SNOMEDCT_US |
3823007 | SNOMEDCT_US |
395843006 | SNOMEDCT_US |
79129001 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Prochlorperazine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-5105 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 14 sections |
Prochlorperazine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-5110 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 14 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-8190 | TABLET | 5 mg | ORAL | ANDA | 12 sections |
Compro | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-7226 | SUPPOSITORY | 25 mg | RECTAL | ANDA | 19 sections |
Prochlorperazine Edisylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6135 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 18 sections |
Prochlorperazine Edisylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6135 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 18 sections |
Prochlorperazine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0713-0135 | SUPPOSITORY | 25 mg | RECTAL | ANDA | 13 sections |
Prochlorperazine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0713-0135 | SUPPOSITORY | 25 mg | RECTAL | ANDA | 13 sections |
Prochlorperazine Edisylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0713-0351 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 13 sections |
Prochlorperazine Edisylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0713-0351 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 13 sections |
Prochlorperazine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-5020 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 18 sections |
Prochlorperazine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-5021 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 18 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-281 | TABLET | 10 mg | ORAL | ANDA | 12 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-511 | TABLET | 5 mg | ORAL | ANDA | 12 sections |
Prochlorperazine Edisylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14789-700 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 18 sections |
PROCHLORPERAZINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-327 | TABLET | 10 mg | ORAL | ANDA | 10 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-571 | TABLET | 5 mg | ORAL | ANDA | 12 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-572 | TABLET | 10 mg | ORAL | ANDA | 12 sections |
Prochlorperazine Edisylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-294 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 13 sections |
PROCHLORPERAZINE EDISYLATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-497 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 12 sections |
Prochlorperazine Edisylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-523 | INJECTION | 5 mg | INTRAMUSCULAR | ANDA | 13 sections |
PROCHLORPERAZINE EDISYLATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-790 | INJECTION | 5 mg | INTRAVENOUS | ANDA | 18 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-141 | TABLET | 5 mg | ORAL | ANDA | 12 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-550 | TABLET | 10 mg | ORAL | ANDA | 12 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-728 | TABLET | 5 mg | ORAL | ANDA | 12 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-729 | TABLET | 10 mg | ORAL | ANDA | 12 sections |
Prochlorperazine maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42708-103 | TABLET | 10 mg | ORAL | ANDA | 12 sections |
Prochlorperazine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-353 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 14 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-742 | TABLET | 10 mg | ORAL | ANDA | 12 sections |
PROCHLORPERAZINE MALEATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-742 | TABLET | 10 mg | ORAL | ANDA | 12 sections |